[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 11503
51. Eve HE, Linch D, Qian W, Ross M, Seymour JF, Smith P, Stevens L, Rule SA: Toxicity of fludarabine and cyclophosphamide with or without rituximab as initial therapy for patients with previously untreated mantle cell lymphoma: results of a randomised phase II study. Leuk Lymphoma; 2009 Feb;50(2):211-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The combination of FC is well-recognised as significantly immunosuppressive and there are concerns that adding rituximab may increase infection risk further.
  • Non-hematological toxicity was similar between the two treatment arms.

  • Genetic Alliance. consumer health - Mantle cell lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19197729.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] ENG
  • [Grant] United Kingdom / Cancer Research UK / / 5665; United Kingdom / Cancer Research UK / /
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 4F4X42SYQ6 / Rituximab; 8N3DW7272P / Cyclophosphamide; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


52. Gaskett AC, Winnick CG, Herberstein ME: Orchid sexual deceit provokes ejaculation. Am Nat; 2008 Jun;171(6):E206-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The costs of sperm wastage could select for pollinator avoidance of orchids, thereby driving and maintaining sexual deception via antagonistic coevolution or an arms race between pollinator learning and escalating orchid mimicry.


53. Minc N, Viovy JL, Dorfman KD: Non-markovian transport of DNA in microfluidic post arrays. Phys Rev Lett; 2005 May 20;94(19):198105
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The motion is a repetitive three-part cycle: (i) collision with the post and extension of the arms;.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16090219.001).
  • [ISSN] 0031-9007
  • [Journal-full-title] Physical review letters
  • [ISO-abbreviation] Phys. Rev. Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral
  •  go-up   go-down


5
Advertisement
4. Brinkman SA, Johnson SE, Lawrence D, Codde JP, Hart MB, Straton JA, Silburn S: Study protocol for the evaluation of an Infant Simulator based program delivered in schools: a pragmatic cluster randomised controlled trial. Trials; 2010;11:100
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this trial is to evaluate the Virtual Infant Parenting (VIP) program by investigating pre-conceptual health and risk behaviours, teen pregnancy and the resultant birth outcomes, early child health and maternal health.
  • METHODS AND DESIGN: Fifty-seven schools (86% of 66 eligible secondary schools) in Perth, Australia were recruited to the clustered (by school) randomised trial, with even randomisation to the intervention and control arms.
  • Kaplan-Meier survival analysis and proportional hazards regression will test for differences in pregnancy, birth and abortion rates during the teenage years between the study arms.


55. Acuna M, Amasay T, Karduna AR: The reliability of side to side measurements of upper extremity activity levels in healthy subjects. BMC Musculoskelet Disord; 2010 Jul 22;11:168
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Each subject wore a triaxial accelerometer on both arms for three and a half hours.
  • CONCLUSIONS: In general, the mean activity levels during daily activities were very similar between dominant and non-dominant arms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Neurol Phys Ther. 2007 Jun;31(2):56-63 [17558358.001]
  • [Cites] J Electromyogr Kinesiol. 2007 Aug;17(4):410-9 [16839778.001]
  • [Cites] Gait Posture. 2010 Feb;31(2):256-60 [19945285.001]
  • [Cites] Behav Res Methods. 2007 May;39(2):175-91 [17695343.001]
  • [Cites] Med Biol Eng Comput. 2008 Feb;46(2):169-78 [18087742.001]
  • [Cites] IEEE Trans Biomed Eng. 2008 Feb;55(2 Pt 1):746-54 [18270013.001]
  • [Cites] Gait Posture. 2008 Apr;27(3):368-75 [17582769.001]
  • [Cites] Phys Ther. 2008 May;88(5):652-63 [18326055.001]
  • [Cites] Comput Methods Biomech Biomed Engin. 2008 Jun;11(3):235-42 [18568821.001]
  • [Cites] Gait Posture. 2008 Nov;28(4):581-7 [18547809.001]
  • [Cites] J Orthop Sports Phys Ther. 2008 Oct;38(10):640-5 [18827326.001]
  • [Cites] Med Biol Eng Comput. 2009 May;47(5):467-74 [19277750.001]
  • [Cites] Appl Ergon. 1999 Dec;30(6):495-503 [10693829.001]
  • [Cites] J Neurophysiol. 2000 May;83(5):2661-75 [10805666.001]
  • [Cites] Scand J Work Environ Health. 2000 Aug;26(4):283-91 [10994793.001]
  • [Cites] Appl Ergon. 2001 Jun;32(3):215-24 [11394462.001]
  • [Cites] J Shoulder Elbow Surg. 2001 May-Jun;10(3):242-6 [11408905.001]
  • [Cites] Scand J Work Environ Health. 2001 Dec;27(6):373-80 [11800324.001]
  • [Cites] Med Biol Eng Comput. 2002 Mar;40(2):173-82 [12043798.001]
  • [Cites] Appl Ergon. 2002 Nov;33(6):541-7 [12507338.001]
  • [Cites] Pain. 2003 Jan;101(1-2):79-88 [12507702.001]
  • [Cites] AIHA J (Fairfax, Va). 2003 Mar-Apr;64(2):196-211 [12688844.001]
  • [Cites] Ergonomics. 2003 Jun 20;46(8):800-24 [12745980.001]
  • [Cites] Ergonomics. 2004 Jan 15;47(1):19-40 [14660216.001]
  • [Cites] Physiol Meas. 2004 Apr;25(2):R1-20 [15132305.001]
  • [Cites] Exp Brain Res. 2004 Jun;156(3):325-32 [14745465.001]
  • [Cites] Brain Cogn. 2004 Jul;55(2):349-51 [15177810.001]
  • [Cites] Occup Environ Med. 2004 Oct;61(10):844-53 [15377771.001]
  • [Cites] Arthritis Rheum. 2004 Oct;50(10):3314-22 [15476229.001]
  • [Cites] Neuropsychologia. 1971 Mar;9(1):97-113 [5146491.001]
  • [Cites] Lancet. 1986 Feb 8;1(8476):307-10 [2868172.001]
  • [Cites] Ergonomics. 1991 Dec;34(12):1455-68 [1800110.001]
  • [Cites] Neuropsychologia. 1992 Jul;30(7):601-8 [1528408.001]
  • [Cites] Am J Ind Med. 1995 May;27(5):731-47 [7611308.001]
  • [Cites] Stroke. 1996 Sep;27(9):1564-70 [8784131.001]
  • [Cites] Scand J Work Environ Health. 1995 Dec;21(6):440-9 [8824750.001]
  • [Cites] Ergonomics. 1996 Oct;39(10):1221-30 [8974883.001]
  • [Cites] Phys Ther. 1997 Jul;77(7):745-50 [9225846.001]
  • [Cites] Arch Phys Med Rehabil. 1999 Feb;80(2):155-61 [10025489.001]
  • [Cites] Arch Phys Med Rehabil. 2005 Mar;86(3):541-8 [15759242.001]
  • [Cites] Arch Phys Med Rehabil. 2005 Jul;86(7):1498-501 [16003690.001]
  • [Cites] Med Sci Sports Exerc. 2005 Nov;37(11 Suppl):S490-500 [16294112.001]
  • [Cites] J Electromyogr Kinesiol. 2006 Apr;16(2):125-36 [16102977.001]
  • [Cites] J Bone Joint Surg Am. 2006 Aug;88(8):1699-704 [16882890.001]
  • [Cites] Med Biol Eng Comput. 2006 Jun;44(6):479-87 [16937199.001]
  • [Cites] Physiol Meas. 2006 Oct;27(10):999-1008 [16951459.001]
  • [Cites] Brain Res. 2009 Nov 17;1298:78-91 [19728993.001]
  • (PMID = 20650006.001).
  • [ISSN] 1471-2474
  • [Journal-full-title] BMC musculoskeletal disorders
  • [ISO-abbreviation] BMC Musculoskelet Disord
  • [Language] ENG
  • [Grant] United States / NIOSH CDC HHS / OH / 5R01OH008288
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2914700
  •  go-up   go-down


56. Khan FA, Minion J, Pai M, Royce S, Burman W, Harries AD, Menzies D: Treatment of active tuberculosis in HIV-coinfected patients: a systematic review and meta-analysis. Clin Infect Dis; 2010 May 1;50(9):1288-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Patients with human immunodeficiency virus (HIV) infection and tuberculosis have an increased risk of death, treatment failure, and relapse.
  • In included studies, the initial tuberculosis diagnosis, failure, and/or relapse were microbiologically confirmed, and patients received standardized rifampin- or rifabutin-containing regimens.
  • Relapse was more common with regimens using 2 months rifamycin (adjusted risk ratio, 3.6; 95% confidence interval, 1.1-11.7) than with regimens using rifamycin for at least 8 months.
  • Compared with daily therapy in the initial phase (n=3352 patients from 35 study arms), thrice-weekly therapy (n=211 patients from 5 study arms) was associated with higher rates of failure (adjusted risk ratio, 4.0; 95% confidence interval, 1.5-10.4) and relapse [adjusted risk ratio, 4.8; 95% confidence interval, 1.8-12.8).

  • Genetic Alliance. consumer health - Tuberculosis.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • MedlinePlus Health Information. consumer health - HIV/AIDS Medicines.
  • MedlinePlus Health Information. consumer health - Tuberculosis.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RIFAMPIN .
  • PubMed Health. DARE review .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20353364.001).
  • [ISSN] 1537-6591
  • [Journal-full-title] Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • [ISO-abbreviation] Clin. Infect. Dis.
  • [Language] eng
  • [Grant] Canada / Canadian Institutes of Health Research / /
  • [Publication-type] Journal Article; Meta-Analysis; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-HIV Agents; 0 / Antitubercular Agents; VJT6J7R4TR / Rifampin
  • [Number-of-references] 67
  •  go-up   go-down


57. Milla P, Airoldi M, Weber G, Drescher A, Jaehde U, Cattel L: Administration of reduced glutathione in FOLFOX4 adjuvant treatment for colorectal cancer: effect on oxaliplatin pharmacokinetics, Pt-DNA adduct formation, and neurotoxicity. Anticancer Drugs; 2009 Jun;20(5):396-402
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There were no significant differences in the main pharmacokinetic parameters between the two arms except a lower area under the plasma concentration-time curve and a smaller apparent steady-state volume of distribution (Vss) when GSH was coadministered.
  • The determination of Pt-DNA adduct formation shows no statistically significant differences between the two arms.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Colorectal Neoplasms / drug therapy. DNA Adducts / drug effects. Glutathione / pharmacology. Organoplatinum Compounds / pharmacokinetics. Peripheral Nervous System Diseases / prevention & control

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Peripheral Nerve Disorders.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19287306.001).
  • [ISSN] 1473-5741
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / DNA Adducts; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; GAN16C9B8O / Glutathione; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; Folfox protocol
  •  go-up   go-down


58. Ardizzoni A, Favaretto A, Boni L, Baldini E, Castiglioni F, Antonelli P, Pari F, Tibaldi C, Altieri AM, Barbera S, Cacciani G, Raimondi M, Tixi L, Stefani M, Monfardini S, Antilli A, Rosso R, Paccagnella A: Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto (FONICAP-GSTPV) study. J Clin Oncol; 2005 Jan 20;23(3):569-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: Small-cell lung cancer (SCLC) is increasingly diagnosed in elderly patients, who are at higher risk of treatment-related morbidity and mortality.
  • Seventy-five percent and 72% of the patients in the AD and FD arms, respectively, completed the treatment as per protocol.
  • Response rate was 39% and 69% in the AD and FD arms, respectively, and 1-year survival probability was 18% and 39%, respectively.

  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15659503.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; 6WS4C399GB / lenograstim; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


59. Jung JY, Yeom KB, Eun HC: Chemical Leukoderma Improved by Low-dose Steroid Pulse Therapy. Ann Dermatol; 2010 May;22(2):241-4
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report a healthy 51-year-old man who had multiple hypopigmented macules and patches on his face, neck, arms and legs after exposure to occupationally related chemicals.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Dermatol. 2009 Jan;160(1):40-7 [18782317.001]
  • [Cites] Br J Dermatol. 2008 Nov;159(5):1051-76 [19036036.001]
  • [Cites] Pigment Cell Res. 2006 Oct;19(5):406-11 [16965269.001]
  • [Cites] Contact Dermatitis. 1999 Aug;41(2):94-8 [10445689.001]
  • [Cites] Int J Dermatol. 1999 Jul;38(7):546-50 [10440289.001]
  • [Cites] J Am Acad Dermatol. 2001 May;44(5):814-7 [11312430.001]
  • [Cites] J Occup Med. 1970 Oct;12(10):386-9 [4248935.001]
  • [Cites] Arch Dermatol. 1970 Aug;102(2):177-87 [5430313.001]
  • [Cites] Pigment Cell Res. 2004 Jun;17(3):208-14 [15140065.001]
  • [Cites] Pigment Cell Res. 2003 Aug;16(4):322-32 [12859615.001]
  • [Cites] Trans St Johns Hosp Dermatol Soc. 1971;57(1):115-34 [4255068.001]
  • (PMID = 20548927.001).
  • [ISSN] 2005-3894
  • [Journal-full-title] Annals of dermatology
  • [ISO-abbreviation] Ann Dermatol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2883439
  • [Keywords] NOTNLM ; Chemical leukoderma / Systemic steroid / Vitiligo
  •  go-up   go-down


60. Jia J, Yang Z, Li G, Liu Ch, Lei M, Zhang T, Zhou J, Ren Z: Isolation and chromosomal distribution of a novel Ty1-copia-like sequence from Secale, which enables identification of wheat-Secale africanum introgression lines. J Appl Genet; 2009;50(1):25-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fluorescence in situ hybridization (FISH) analyses indicated that pSaO5411 was significantly hybridized to S. africanum chromosomes of a wheat-S. africanum amphiploid, and it was dispersed along the Secale chromosome arms except the terminal regions.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome. 1997 Oct;40(5):617-25 [9352643.001]
  • [Cites] Chromosome Res. 2001;9(2):129-36 [11321368.001]
  • [Cites] Genetica. 1997;100(1-3):205-17 [9440274.001]
  • [Cites] Genome. 2001 Apr;44(2):266-74 [11341737.001]
  • [Cites] Genome. 2002 Feb;45(1):157-64 [11908658.001]
  • [Cites] Genome. 2004 Aug;47(4):747-56 [15284880.001]
  • [Cites] Plant J. 1998 Dec;16(6):721-8 [10069078.001]
  • [Cites] Hereditas. 2005 Feb;142(2005):80-5 [16970616.001]
  • [Cites] Genetica. 1997;100(1-3):197-204 [9440273.001]
  • [Cites] Genome. 1997 Jun;40(3):309-17 [9202411.001]
  • [Cites] Genome. 1995 Aug;38(4):795-802 [7672610.001]
  • [Cites] Annu Rev Genet. 1999;33:479-532 [10690416.001]
  • [Cites] Genome. 1990 Oct;33(5):635-40 [2262137.001]
  • (PMID = 19193979.001).
  • [ISSN] 1234-1983
  • [Journal-full-title] Journal of applied genetics
  • [ISO-abbreviation] J. Appl. Genet.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Chromatin; 0 / Genetic Markers; 0 / Retroelements
  •  go-up   go-down


61. Galaup C, Couchet JM, Bedel S, Tisnès P, Picard C: Direct access to terpyridine-containing polyazamacrocycles as photosensitizing ligands for Eu(III) luminescence in aqueous media. J Org Chem; 2005 Mar 18;70(6):2274-84
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [reaction: see text] The synthesis of new 18-membered hexaazamacrocycles containing a functionalized 2,2':6',2' '-terpyridine moiety as part of the cyclic backbone and three acetate pendant arms is described.

  • Hazardous Substances Data Bank. Water .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15760215.001).
  • [ISSN] 0022-3263
  • [Journal-full-title] The Journal of organic chemistry
  • [ISO-abbreviation] J. Org. Chem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Aza Compounds; 0 / Hydrocarbons, Cyclic; 0 / Ligands; 0 / Organometallic Compounds; 0 / Pyridines; 059QF0KO0R / Water; 444W947O8O / Europium; G5E357ISH5 / 2,2',2''-terpyridine
  •  go-up   go-down


62. Shishimi G, Nakajima S: Contextual control of rats' foraging behaviour in a radial maze. Behav Processes; 2007 Jan 10;74(1):97-103
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Four of the eight arms were context-dependent: two arms were baited in the "night" context, while the other two were baited in the "daytime" context.
  • The remaining four arms were context-independent: three of them were never baited, while the remaining one was baited in both contexts.
  • The rats gradually began to avoid the arms that were uniquely baited in the other context, suggesting a contextual or conditional control of arm selection.
  • Interestingly, these rats also showed better performance in avoiding the never-baited arms, compared with control rats.
  • Namely, disambiguating the incentive values of the four arms by contextual cues collaterally facilitated the context-independent arm performance.
  • Another interesting finding of the present study is that the rats did not visit the always-baited arm earlier than the arms uniquely baited in that context.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17140749.001).
  • [ISSN] 0376-6357
  • [Journal-full-title] Behavioural processes
  • [ISO-abbreviation] Behav. Processes
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  •  go-up   go-down


63. Hui HE, Beals TC, Brown NA: Influence of tendon transfer site on moment arms of the flexor digitorum longus muscle. Foot Ankle Int; 2007 Apr;28(4):441-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influence of tendon transfer site on moment arms of the flexor digitorum longus muscle.
  • The purpose of this study was to calculate FDL muscle moment arms at the hindfoot with two clinically relevant transfer locations to quantify the change in mechanical advantage of the FDL after tendon transfer.
  • METHODS: In seven cadaver specimens, muscle moment arms of the FDL with respect to hindfoot motion were measured using the tendon excursion method before and after the FDL was transferred to the plantar aspect of the navicular and medial cuneiform.
  • The position and orientation of the foot and excursion of the FDL tendon were measured with an optoelectronic measurement system.
  • CONCLUSIONS: In contrast to the clinical proposition that FDL transfer to the navicular or medial cuneiform increases this muscle's mechanical advantage to invert the hindfoot, this cadaver study suggests that, to the contrary, FDL muscle moment arms decrease after tendon transfer.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17475138.001).
  • [ISSN] 1071-1007
  • [Journal-full-title] Foot & ankle international
  • [ISO-abbreviation] Foot Ankle Int
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


64. Gabos PG: Modified technique for the surgical treatment of congenital constriction bands of the arms and legs of infants and children. Orthopedics; 2006 May;29(5):401-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modified technique for the surgical treatment of congenital constriction bands of the arms and legs of infants and children.
  • The combination of circumferential subcutaneous fat advancement flaps and Z-plasties allows for single-stage treatment of congenital constriction bands of the arms and legs of infants and children.

  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16729738.001).
  • [ISSN] 0147-7447
  • [Journal-full-title] Orthopedics
  • [ISO-abbreviation] Orthopedics
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Smith ML, Gourdon D, Little WC, Kubow KE, Eguiluz RA, Luna-Morris S, Vogel V: Force-induced unfolding of fibronectin in the extracellular matrix of living cells. PLoS Biol; 2007 Oct 2;5(10):e268
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fn extensibility under the influence of cell traction forces has been proposed to originate either from the force-induced lengthening of an initially compact, folded quaternary structure as is found in solution (quaternary structure model, where the dimeric arms of Fn cross each other), or from the force-induced unfolding of type III modules (unfolding model).
  • The compactly folded quaternary structure with crossed Fn arms, however, was never detected within extracellular matrix fibrils.
  • We conclude that the resting state of Fn fibrils does not contain Fn molecules with crossed-over arms, and that the several-fold extensibility of Fn fibrils involves the unfolding of type III modules.

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Cell Biol. 2000 Mar 6;148(5):1075-90 [10704455.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Mar 2;96(5):2153-8 [10051610.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 May 8;98(10):5590-5 [11331785.001]
  • [Cites] J Cell Biol. 2001 Sep 3;154(5):1081-8 [11535624.001]
  • [Cites] Nat Rev Mol Cell Biol. 2001 Nov;2(11):793-805 [11715046.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14464-8 [11717404.001]
  • [Cites] Matrix Biol. 2002 Mar;21(2):139-47 [11852230.001]
  • [Cites] J Cell Sci. 2002 Mar 15;115(Pt 6):1221-9 [11884521.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Apr 16;99(8):5139-43 [11959962.001]
  • [Cites] J Mol Biol. 2002 May 31;319(2):433-47 [12051919.001]
  • [Cites] J Cell Sci. 2002 Oct 15;115(Pt 20):3861-3 [12244123.001]
  • [Cites] Nature. 2002 Oct 17;419(6908):743-7 [12384704.001]
  • [Cites] J Mol Biol. 2002 Nov 8;323(5):939-50 [12417205.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Dec 9;100(25):14784-9 [14657397.001]
  • [Cites] Structure. 2004 Jan;12(1):21-30 [14725762.001]
  • [Cites] J Biomed Mater Res A. 2004 Jun 1;69(3):525-34 [15127399.001]
  • [Cites] Proc Natl Acad Sci U S A. 1967 Aug;58(2):719-26 [5233469.001]
  • [Cites] J Biol Chem. 1979 Mar 10;254(5):1501-5 [762148.001]
  • [Cites] J Mol Biol. 1981 Jul 25;150(1):97-120 [6795355.001]
  • [Cites] J Cell Biol. 1983 Aug;97(2):466-72 [6309861.001]
  • [Cites] J Biol Chem. 1983 Dec 10;258(23):14539-44 [6643500.001]
  • [Cites] Arch Biochem Biophys. 1985 May 1;238(2):652-63 [3994396.001]
  • [Cites] Biochemistry. 1988 May 3;27(9):3483-7 [3390446.001]
  • [Cites] Biochemistry. 1990 Apr 3;29(13):3354-61 [2334697.001]
  • [Cites] Biochem J. 1990 Aug 15;270(1):33-8 [2396990.001]
  • [Cites] J Mol Biol. 1993 Mar 20;230(2):625-40 [8464068.001]
  • [Cites] Biomaterials. 1993 Aug;14(10):743-8 [8218723.001]
  • [Cites] J Mol Biol. 1994 Jan 28;235(4):1302-11 [8308892.001]
  • [Cites] Nature. 1994 Jan 13;367(6459):193-6 [8114919.001]
  • [Cites] J Biol Chem. 1999 May 28;274(22):15473-9 [10336438.001]
  • [Cites] J Mol Biol. 2005 Jan 28;345(4):817-26 [15588828.001]
  • [Cites] J Biomed Mater Res A. 2005 Feb 1;72(2):146-60 [15558555.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 22;102(8):2754-9 [15699337.001]
  • [Cites] Nature. 2005 Aug 4;436(7051):647-54 [16079835.001]
  • [Cites] Matrix Biol. 2005 Sep;24(6):389-99 [16061370.001]
  • [Cites] Biomaterials. 2006 Feb;27(5):679-90 [16095684.001]
  • [Cites] J Biol Chem. 2005 Oct 28;280(43):36483-93 [16115889.001]
  • [Cites] J Biol Chem. 2005 Nov 25;280(47):39143-51 [16195231.001]
  • [Cites] Matrix Biol. 2006 Apr;25(3):175-84 [16343877.001]
  • [Cites] Nat Rev Mol Cell Biol. 2006 Apr;7(4):265-75 [16607289.001]
  • [Cites] Annu Rev Biophys Biomol Struct. 2006;35:459-88 [16689645.001]
  • [Cites] Cell. 2006 Dec 1;127(5):1015-26 [17129785.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Oct 26;96(22):12518-23 [10535954.001]
  • [Cites] Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):10114-8 [7937847.001]
  • [Cites] Cell. 1996 Jan 12;84(1):155-64 [8548820.001]
  • [Cites] J Biol Chem. 1997 Mar 7;272(10):6159-66 [9045628.001]
  • [Cites] Structure. 1997 Mar 15;5(3):359-70 [9083105.001]
  • [Cites] Scanning. 1997 Aug;19(5):349-55 [9262019.001]
  • [Cites] J Biol Chem. 1998 Jan 30;273(5):2601-9 [9446562.001]
  • [Cites] J Cell Biol. 1998 Apr 20;141(2):539-51 [9548730.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Dec 19;97(26):14241-4 [11121030.001]
  • (PMID = 17914904.001).
  • [ISSN] 1545-7885
  • [Journal-full-title] PLoS biology
  • [ISO-abbreviation] PLoS Biol.
  • [Language] eng
  • [Grant] United States / NEI NIH HHS / EY / PN2 EY016586
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fibronectins
  • [Other-IDs] NLM/ PMC1994993
  •  go-up   go-down


66. Ishizuka Y, Abe H, Tanoue A, Kannan H, Ishida Y: Involvement of vasopressin V1b receptor in anti-anxiety action of SSRI and SNRI in mice. Neurosci Res; 2010 Mar;66(3):233-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Previous studies showed that AVP facilitates aggression while serotonin inhibits aggression by blocking the activity of the vasopressin system.
  • To examine whether the interaction of the V1bR and serotonin in the central nervous system controls anxiety-related behavior, we investigated the effects of acute and chronic treatment with a selective serotonin reuptake inhibitor (SSRI) and with a serotonin noradrenalin reuptake inhibitor (SNRI) on V1bR knockout (KO) mice and on V1bR antagonist (SSR149415)-treated mice.
  • For both the V1bR KO mice and V1bR antagonist-treated mice, acute treatment with either SSRI or SNRI did not change the time spent on the EPM open arms or the number of head dips in the HB.
  • Chronic treatment of V1bR KO mice with SSRI did not change the amount of time spent on the open arms, the number of head dips, or the number of rearings, while chronic treatment with SNRI significantly increased the time spent on the open arms and the number of head dips.

  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19914307.001).
  • [ISSN] 1872-8111
  • [Journal-full-title] Neuroscience research
  • [ISO-abbreviation] Neurosci. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / 1-(5-chloro-1-((2,4-dimethoxyphenyl)sulfonyl)-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl)-4-hydroxy-N,N-dimethyl-2-pyrrolidinecarboxamide; 0 / Antidiuretic Hormone Receptor Antagonists; 0 / Indoles; 0 / Neurotransmitter Uptake Inhibitors; 0 / Pyrrolidines; 0 / Receptors, Vasopressin; 0 / Serotonin Uptake Inhibitors; 333DO1RDJY / Serotonin
  •  go-up   go-down


67. Chanan-Khan A, Sonneveld P, Schuster MW, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Neuwirth R, Anderson KC, Richardson PG: Analysis of herpes zoster events among bortezomib-treated patients in the phase III APEX study. J Clin Oncol; 2008 Oct 10;26(29):4784-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most herpes zoster infections were grade 1/2; incidences of grade 3/4 events (1.8% v 1.5%) and infections considered serious adverse events (1.5% v 0.9%) were similar between treatment arms, and no herpes zoster-related deaths occurred.
  • Neither the time to onset of the herpes event nor the patients' absolute lymphocyte counts at baseline differed significantly between arms.
  • The incidence of non-VZV-related herpes viral infections was comparable between arms.
  • No additional risk factors for herpes zoster reactivation were identified.
  • CONCLUSION: Further studies are needed to explain these observations and their implications; however, for patients treated with bortezomib or bortezomib-containing regimens, the risk of VZV reactivation should be monitored and routine use of antiviral prophylaxis considered.

  • MedlinePlus Health Information. consumer health - Multiple Myeloma.
  • MedlinePlus Health Information. consumer health - Shingles.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2009 May 1;27(13):2293-4; author reply 2294-6 [19307496.001]
  • (PMID = 18711175.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


68. Koeberle D, Thuerlimann B: Letrozole as upfront endocrine therapy for postmenopausal women with hormone-sensitive breast cancer: BIG 1-98. Breast Cancer Res Treat; 2007;105 Suppl 1:55-66
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • This pre-planned core analysis allowed the use of patient data from the monotherapy arms of letrozole and tamoxifen and from the sequential arms prior to the drug switch point.
  • Patients randomized to letrozole had a 19% improved disease-free survival (hazard ratio [HR]=0.81; P=0.003), due especially to reduced distant metastases (HR=0.73; P=0.001).
  • A 14% risk reduction of fatal events in favor of letrozole was also observed (P=NS).
  • The results from the monotherapy arms alone confirmed the findings from the primary core analysis.
  • Based on the results from this trial, the aromatase inhibitor letrozole (Femara) is currently recommended as a part of standard adjuvant therapy for postmenopausal women with endocrine-responsive breast cancer and has recently been approved in the early adjuvant setting in both Europe and the United States.
  • [MeSH-minor] Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Disease-Free Survival. Double-Blind Method. Drug Administration Schedule. Europe. Female. Humans. Middle Aged. Neoadjuvant Therapy. Postmenopause. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. TAMOXIFEN .
  • Hazardous Substances Data Bank. LETROZOLE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Oct 1;63(19):6523-31 [14559846.001]
  • [Cites] Cancer. 2003 Nov 1;98(9):1802-10 [14584060.001]
  • [Cites] N Engl J Med. 2003 Nov 6;349(19):1793-802 [14551341.001]
  • [Cites] Breast Cancer Res Treat. 2003 Nov;82(2):103-11 [14692654.001]
  • [Cites] N Engl J Med. 2004 Mar 11;350(11):1081-92 [15014181.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):456-65 [15026471.001]
  • [Cites] Neurology. 2004 Oct 12;63(7):1230-3 [15477543.001]
  • [Cites] Oncologist. 2004;9(5):489-96 [15477633.001]
  • [Cites] Oncology. 1981;38(5):281-5 [7266969.001]
  • [Cites] J Clin Endocrinol Metab. 1982 Feb;54(2):404-8 [6798066.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3748-57 [11078487.001]
  • [Cites] J Clin Oncol. 2000 Nov 15;18(22):3758-67 [11078488.001]
  • [Cites] Am J Clin Pathol. 2001 Jan;115(1):44-58 [11190807.001]
  • [Cites] J Natl Cancer Inst. 2001 May 2;93(9):684-90 [11333290.001]
  • [Cites] J Clin Oncol. 2002 Feb 1;20(3):751-7 [11821457.001]
  • [Cites] Lancet. 2002 Jun 22;359(9324):2131-9 [12090977.001]
  • [Cites] J Clin Oncol. 2003 Jun 1;21(11):2101-9 [12775735.001]
  • [Cites] Ann Oncol. 2003 Sep;14(9):1391-8 [12954578.001]
  • [Cites] J Natl Cancer Inst. 1994 Apr 6;86(7):527-37 [8133536.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2731-7 [8874334.001]
  • [Cites] Ann Oncol. 1996 Sep;7(7):671-5 [8905024.001]
  • [Cites] Breast Cancer Res Treat. 2005 Mar;90(2):127-37 [15803359.001]
  • [Cites] Lancet. 2005 May 14-20;365(9472):1687-717 [15894097.001]
  • [Cites] J Natl Cancer Inst. 2005 Sep 7;97(17):1262-71 [16145047.001]
  • [Cites] J Clin Oncol. 2005 Oct 20;23(30):7512-7 [16234518.001]
  • [Cites] Crit Rev Oncol Hematol. 2006 Jan;57(1):53-61 [16337805.001]
  • [Cites] N Engl J Med. 2005 Dec 29;353(26):2747-57 [16382061.001]
  • [Cites] Eur J Cancer. 2007 Feb;43(3):497-509 [17223541.001]
  • [Cites] J Clin Oncol. 2007 Feb 10;25(5):486-92 [17200148.001]
  • [Cites] Lancet. 2007 Feb 17;369(9561):559-70 [17307102.001]
  • [Cites] Ann Oncol. 2007 May;18(5):859-67 [17301074.001]
  • [Cites] Ann Oncol. 2007 Jul;18(7):1133-44 [17675394.001]
  • [Cites] J Clin Oncol. 2007 Dec 20;25(36):5715-22 [17998546.001]
  • [ErratumIn] Breast Cancer Res Treat. 2008 Nov;112(2):387
  • (PMID = 17912636.001).
  • [ISSN] 0167-6806
  • [Journal-full-title] Breast cancer research and treatment
  • [ISO-abbreviation] Breast Cancer Res. Treat.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 0 / Aromatase Inhibitors; 0 / Nitriles; 0 / Triazoles; 094ZI81Y45 / Tamoxifen; 7LKK855W8I / letrozole
  • [Other-IDs] NLM/ PMC2001218
  •  go-up   go-down


69. Roach M 3rd: Dose escalated external beam radiotherapy versus neoadjuvant androgen deprivation therapy and conventional dose external beam radiotherapy for clinically localized prostate cancer: do we need both? Strahlenther Onkol; 2007 Dec;183 Spec No 2:26-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • MATERIALS AND METHODS: To date 4 randomized trials, including 10 arms and approximately 1600 men have reported comparing patients treated with EBRT alone to EBRT combined with short-term NADT.
  • To date, four Phase III dose escalation trials have been completed including 8 arms and a total of approximately 2210 patients with doses up to 74 to 79 Gy compared to doses of 64 to 70 Gy on the control arms.
  • [MeSH-minor] Antineoplastic Agents, Hormonal / therapeutic use. Clinical Trials, Phase III as Topic. Follow-Up Studies. Humans. Male. Neoadjuvant Therapy. Neoplasm Metastasis. Prospective Studies. Prostate-Specific Antigen / blood. Radiotherapy Dosage. Randomized Controlled Trials as Topic. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Prostate cancer.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167004.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Androgen Antagonists; 0 / Antineoplastic Agents, Hormonal; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Number-of-references] 18
  •  go-up   go-down


70. Iwata E, Kikusui T, Takeuchi Y, Mori Y: Fostering and environmental enrichment ameliorate anxious behavior induced by early weaning in Balb/c mice. Physiol Behav; 2007 Jun 8;91(2-3):318-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In elevated plus-maze tests, 10-week-old pups reared with a foster mother spent more time in the open arms than early-weaned mice, and entered into the open arms at a rate between that of normally- and early-weaned mice.
  • The enriched environment increased the duration of time spent in the open arms, but the magnitude of the effect varied with the rearing condition.

  • MedlinePlus Health Information. consumer health - Anxiety.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17434546.001).
  • [ISSN] 0031-9384
  • [Journal-full-title] Physiology & behavior
  • [ISO-abbreviation] Physiol. Behav.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


71. Oda M, Uchiyama S, Robinson CV, Fukui K, Kobayashi Y, Azuma T: Regional and segmental flexibility of antibodies in interaction with antigens of different size. FEBS J; 2006 Apr;273(7):1476-87
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • When both Abs and Ags were free in solution, sedimentation equilibrium and surface plasmon resonance analyses showed the formation of an Ag(2)Ab(1) complexes regardless of Ag size, suggesting that the Fab arms were able to move to avoid interference between Ags bound to Ab combining sites.
  • These results indicated that immobilization of the Fc region reduces the dynamic range of the Fab arms and results in interference from the first Ag bound to either combining site, which in turn prevents the binding of the second Ag to the other combining site.
  • Our results allow us to propose that the Fab arms of B-cell receptors whose Fc regions are immobilized on cell surface have a reduced dynamic range.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16689933.001).
  • [ISSN] 1742-464X
  • [Journal-full-title] The FEBS journal
  • [ISO-abbreviation] FEBS J.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies; 0 / Antigens; 0 / Multiprotein Complexes; 0 / Serum Albumin; 9006-59-1 / Ovalbumin
  •  go-up   go-down


72. Endo Y, Ohta M, Shibata K, Kai S, Iwaki K, Uchida H, Ogata M, Ikewaki J, Kashima K, Kitano S: Splenectomy for hypersplenism caused by adult T-cell leukemia: report of a case. Surg Today; 2008;38(12):1148-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • A 45-year-old woman with previously diagnosed chronic type adult T-cell leukemia (ATL) presented with abdominal discomfort and red eruptions on her arms and legs.
  • We performed splenectomy in an attempt to reduce the total volume of malignant cells and improve the hypersplenism.
  • Splenectomy should be considered as an optional treatment for hypersplenism caused by ATL when hypersplenism cannot be controlled by chemotherapy in patients without a high surgical risk.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Disease Progression. Erythrocyte Transfusion. Female. Humans. Middle Aged. Platelet Transfusion. Spleen / pathology. Splenomegaly

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Br J Surg. 1990 Apr;77(4):443-9 [2340397.001]
  • [Cites] Proc Natl Acad Sci U S A. 1982 Mar;79(6):2031-5 [6979048.001]
  • [Cites] Curr Treat Options Oncol. 2007 Apr;8(2):109-16 [17680218.001]
  • [Cites] Arch Surg. 2006 Aug;141(8):755-61; discussion 761-2 [16924082.001]
  • [Cites] Am J Surg. 2002 Dec;184(6):631-5; discussion 635-6 [12488196.001]
  • [Cites] Eur J Haematol. 2000 Mar;64(3):145-50 [10997879.001]
  • [Cites] Ann Surg. 2003 Aug;238(2):235-40 [12894017.001]
  • [Cites] Am Surg. 1991 Feb;57(2):108-13 [1992865.001]
  • [Cites] Acta Haematol. 2005;113(4):255-7 [15983432.001]
  • [Cites] Proc Natl Acad Sci U S A. 1981 Oct;78(10):6476-80 [7031654.001]
  • [Cites] Blood. 1977 Sep;50(3):481-92 [301762.001]
  • [Cites] J Cancer Res Clin Oncol. 1983;105(1):106-8 [6601106.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):290-6 [8604910.001]
  • [Cites] Surg Today. 2007;37(1):19-23 [17186340.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):720-3 [3756435.001]
  • [Cites] Br J Haematol. 1991 Nov;79(3):428-37 [1751370.001]
  • (PMID = 19039645.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


73. Kateneva AV, Dresser ME: Sister chromatid cohesion remodeling and meiotic recombination. Cell Cycle; 2006 Mar;5(5):467-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Proper control of cohesion along the chromosome arms is essential for segregation of homologous chromosomes in meiosis.
  • Finding that the same defect in separation of sister chromatids could be suppressed by disrupting the functions of these proteins supports the emerging recognition that cohesion is remodeled during recombination and further indicates that cohesion is modified specifically to regulate meiotic recombination.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16552182.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Grant] United States / NIGMS NIH HHS / GM / GM-45250-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Fungal Proteins
  •  go-up   go-down


74. Ruiz de Angulo V, Torras C: Speeding up the learning of robot kinematics through function decomposition. IEEE Trans Neural Netw; 2005 Nov;16(6):1504-12
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The main drawback of using neural networks or other example-based learning procedures to approximate the inverse kinematics (IK) of robot arms is the high number of training samples (i.e., robot movements) required to attain an acceptable precision.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16342491.001).
  • [ISSN] 1045-9227
  • [Journal-full-title] IEEE transactions on neural networks
  • [ISO-abbreviation] IEEE Trans Neural Netw
  • [Language] ENG
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


75. Mi XJ, Chen SW, Wang WJ, Wang R, Zhang YJ, Li WJ, Li YL: Anxiolytic-like effect of paeonol in mice. Pharmacol Biochem Behav; 2005 Jul;81(3):683-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • As with 2 mg/kg diazepam, paeonol (at 17.5 mg/kg) increased the percentage of time spent on open arms in the elevated plus maze and increased the time spent in the light area of the light/dark box (at 8.75 and 17.5 mg/kg).

  • Hazardous Substances Data Bank. DIAZEPAM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15970315.001).
  • [ISSN] 0091-3057
  • [Journal-full-title] Pharmacology, biochemistry, and behavior
  • [ISO-abbreviation] Pharmacol. Biochem. Behav.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Acetophenones; 0 / Anti-Anxiety Agents; 0 / Muscle Relaxants, Central; 3R834EPI82 / paeonol; Q3JTX2Q7TU / Diazepam
  •  go-up   go-down


76. Jiang WY, Chen LM, Lin QD, Geng Q, Du CS: Denaturing high-performance liquid chromatography technique platform applied to screen G6PD deficient variants. Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2005 Dec;22(6):607-11
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: When applied to screen and identify the G6PD deficient variants from 124 patients who come from 11 nations in China, the DHPLC was compared with amplification refractory mutation system (ARMS) or DNA sequence technique and assessed carefully in its accuracy, sensitivity, efficiency and the cost of experiment.
  • However, ARMS checked 83 positive controls but got 12 false G6PD mutants, of which 5 were false positive, 7 false negative.
  • Above results show that DHPLC sounds like to be more convenience, sensitive and accurate than ARMS and DNA sequence techniques for checking G6PD mutants.
  • [MeSH-major] Chromatography, High Pressure Liquid / methods. Glucosephosphate Dehydrogenase / genetics. Glucosephosphate Dehydrogenase Deficiency / diagnosis
  • [MeSH-minor] DNA Mutational Analysis. Female. Humans. Male. Mutation. Reproducibility of Results

  • MedlinePlus Health Information. consumer health - G6PD Deficiency.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16331553.001).
  • [ISSN] 1003-9406
  • [Journal-full-title] Zhonghua yi xue yi chuan xue za zhi = Zhonghua yixue yichuanxue zazhi = Chinese journal of medical genetics
  • [ISO-abbreviation] Zhonghua Yi Xue Yi Chuan Xue Za Zhi
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 1.1.1.49 / Glucosephosphate Dehydrogenase
  •  go-up   go-down


77. Mandell BF: Influenza: it's right to bare arms. Cleve Clin J Med; 2008 Dec;75(12):830
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Influenza: it's right to bare arms.

  • MedlinePlus Health Information. consumer health - Flu.
  • MedlinePlus Health Information. consumer health - Flu Shot.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Cleve Clin J Med. 2008 Dec;75(12):865-70 [19088005.001]
  • (PMID = 19087988.001).
  • [ISSN] 1939-2869
  • [Journal-full-title] Cleveland Clinic journal of medicine
  • [ISO-abbreviation] Cleve Clin J Med
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Influenza Vaccines
  •  go-up   go-down


78. Lancet's International Advisory Board: Reed Elsevier and the arms trade. Lancet; 2005 Sep 10-16;366(9489):868
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Reed Elsevier and the arms trade.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Lancet. 2005 Sep 10-16;366(9489):889; discussion 889-90 [16154003.001]
  • (PMID = 16153994.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Comment; Editorial
  • [Publication-country] England
  •  go-up   go-down


79. Droz JP, Kramar A, Biron P, Pico JL, Kerbrat P, Pény J, Curé H, Chevreau C, Théodore C, Bouzy J, Culine S, Genito-Urinary Group of the French Federation of Cancer Centers (GETUG): Failure of high-dose cyclophosphamide and etoposide combined with double-dose cisplatin and bone marrow support in patients with high-volume metastatic nonseminomatous germ-cell tumours: mature results of a randomised trial. Eur Urol; 2007 Mar;51(3):739-46; discussion 747-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: In an intent-to-treat analysis, there were 32 (56%) and 24 (42%) complete responses in arms A and B, respectively (p=0.099).
  • After a median follow-up of 9.7 yr, 31 and 27 patients have continuously shown no evidence of disease in arms A and B, respectively.
  • According to the International Germ Cell Cancer Collaborative Group prognostic classification, the 5-yr survival rates were 88% and 82% in the intermediate group and 69% and 44% in the poor group (p=0.045) in arms A and B, respectively.

  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Testicular Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17084512.001).
  • [ISSN] 0302-2838
  • [Journal-full-title] European urology
  • [ISO-abbreviation] Eur. Urol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 6PLQ3CP4P3 / Etoposide; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


80. Park JH, Cha HY, Seo JJ, Hong JT, Han K, Oh KW: Anxiolytic-like effects of ginseng in the elevated plus-maze model: comparison of red ginseng and sun ginseng. Prog Neuropsychopharmacol Biol Psychiatry; 2005 Jul;29(6):895-900
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The RG butanol fraction (100 mg/kg) significantly increased the number of open arms entries and the time spent on the open arm (indicators of anxiolytic-like effects) compared with that of the saline group.
  • However, lower doses of the SG total extract (50 mg/kg) and the SG butanol fraction (25 and 50 mg/kg) significantly increased the number of open arms entries and the time spent on the open arms.
  • The RG total extract (100 mg/kg) and the SG total extract at a lower dose (25 mg/kg) did not increase the number of open arm entries or the time spent on the open arm.
  • [MeSH-minor] Analysis of Variance. Animals. Behavior, Animal / drug effects. Diazepam / therapeutic use. Disease Models, Animal. Dose-Response Relationship, Drug. Drug Compounding / methods. Male. Mice. Mice, Inbred ICR. Motor Activity / drug effects. Plant Extracts / therapeutic use

  • MedlinePlus Health Information. consumer health - Anxiety.
  • Hazardous Substances Data Bank. DIAZEPAM .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16002200.001).
  • [ISSN] 0278-5846
  • [Journal-full-title] Progress in neuro-psychopharmacology & biological psychiatry
  • [ISO-abbreviation] Prog. Neuropsychopharmacol. Biol. Psychiatry
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents; 0 / Plant Extracts; Q3JTX2Q7TU / Diazepam
  •  go-up   go-down


81. Tejada J, Bosco GG, Morato S, Roque AC: Characterization of the rat exploratory behavior in the elevated plus-maze with Markov chains. J Neurosci Methods; 2010 Nov 30;193(2):288-95
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It consists of a plus-shaped maze with two open and two closed arms elevated 50cm from the floor.
  • The standard measures used to characterize exploratory behavior in the elevated plus-maze are the time spent and the number of entries in the open arms.
  • The spatial structure of the elevated plus-maze is divided into squares, which are associated with states of a Markov chain.
  • By counting the frequencies of transitions between states during 5-min sessions in the elevated plus-maze, we constructed stochastic matrices for the three conditions studied.
  • For the control group, the stochastic matrix shows a clear preference for places in the closed arms.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CHLORDIAZEPOXIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Elsevier B.V. All rights reserved.
  • (PMID = 20869398.001).
  • [ISSN] 1872-678X
  • [Journal-full-title] Journal of neuroscience methods
  • [ISO-abbreviation] J. Neurosci. Methods
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents; 0 / Convulsants; 6RZ6XEZ3CR / Chlordiazepoxide; WM5Z385K7T / Pentylenetetrazole
  •  go-up   go-down


82. Suzuki M, Tominaga N, Ide Y, Ohyama A, Nakahara T, Ishikawa H, Tanaka A, Mataga I: Establishment and characterization of the rhabdomyosarcoma cell line designated NUTOS derived from the human tongue sarcoma: Special reference to the susceptibility of anti-cancer drugs. Hum Cell; 2010 May;23(2):65-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment and characterization of the rhabdomyosarcoma cell line designated NUTOS derived from the human tongue sarcoma: Special reference to the susceptibility of anti-cancer drugs.
  • Primary alveolar type of rhabdomyosarcoma (RMS) tumor tissue was collected from the tongue of a 17-year-old Japanese woman and used to successfully establish a rhabdomyosarcoma cell line, which has been designated NUTOS.
  • Histopathological observations of the NUTOS cell grafts in the subcutis of nude mice exhibited characteristics similar to those seen for the primary rhabdomyosarcoma of the tongue.
  • [MeSH-major] Drug Screening Assays, Antitumor. Rhabdomyosarcoma / pathology. Tongue Neoplasms / pathology


83. Ziari M, Sonpavde G, Shen S, Zhai J, Teh BS, Lerner SP: Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult. J Clin Oncol; 2005 Jul 1;23(19):4459-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Patients with unusual bladder malignancies and a rare cause of splenomegaly. Case 2. Rhabdomyosarcoma of the urinary bladder in an adult.
  • [MeSH-major] Rhabdomyosarcoma / diagnosis. Splenomegaly / etiology. Urinary Bladder Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Splenomegaly.
  • MedlinePlus Health Information. consumer health - Bladder Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994156.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


84. Aravin AA, Hannon GJ, Brennecke J: The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race. Science; 2007 Nov 2;318(5851):761-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The Piwi-piRNA pathway provides an adaptive defense in the transposon arms race.
  • As a specific and adaptive regulatory system, RNAi is used throughout eukarya, which indicates a long evolutionary history.

  • COS Scholar Universe. author profiles.
  • FlyBase. FlyBase .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17975059.001).
  • [ISSN] 1095-9203
  • [Journal-full-title] Science (New York, N.Y.)
  • [ISO-abbreviation] Science
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Argonaute Proteins; 0 / DNA Transposable Elements; 0 / Drosophila Proteins; 0 / Proteins; 0 / RNA, Small Interfering; 0 / RNA-Binding Proteins; 0 / RNA-Induced Silencing Complex; 0 / piwi protein, Drosophila
  • [Number-of-references] 38
  •  go-up   go-down


85. Huang P, Liu-Chen LY, Kirby LG: Anxiety-like effects of SR141716-precipitated delta9-tetrahydrocannabinol withdrawal in mice in the elevated plus-maze. Neurosci Lett; 2010 May 21;475(3):165-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, SR141716 precipitated a reduction in exploration of the open arms of EPM in mice repeatedly treated with THC vs vehicle.
  • At 3.0mg/kg, SR141716 significantly reduced % open arm entries of the total arm entries, % open arm time of total time in arms, and the absolute time spent in open arms.

  • MedlinePlus Health Information. consumer health - Anxiety.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. delta 9-Tetrahydrocannabinol .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Ireland Ltd. All rights reserved.
  • [Cites] J Pharmacol Exp Ther. 2001 Sep;298(3):1007-14 [11504797.001]
  • [Cites] Neurosci Lett. 2009 Nov 6;465(1):66-70 [19733208.001]
  • [Cites] Behav Brain Res. 2001 Nov 1;125(1-2):151-7 [11682106.001]
  • [Cites] Pharmacol Ther. 2002 Aug;95(2):153-64 [12182962.001]
  • [Cites] Eur J Neurosci. 2002 Oct;16(7):1395-8 [12405999.001]
  • [Cites] J Clin Pharmacol. 2002 Nov;42(11 Suppl):20S-27S [12412832.001]
  • [Cites] Eur J Neurosci. 2003 Mar;17(6):1279-86 [12670316.001]
  • [Cites] Eur J Neurosci. 2004 Aug;20(4):1059-64 [15305874.001]
  • [Cites] J Pharmacol Exp Ther. 1996 May;277(2):586-94 [8627535.001]
  • [Cites] Pharmacol Biochem Behav. 1996 May;54(1):21-30 [8728535.001]
  • [Cites] Neuroreport. 1997 Jan 20;8(2):491-6 [9080435.001]
  • [Cites] Science. 1997 Jun 27;276(5321):2050-4 [9197270.001]
  • [Cites] J Pharmacol Exp Ther. 1998 Jun;285(3):1150-6 [9618417.001]
  • [Cites] Br J Pharmacol. 1998 Dec;125(7):1567-77 [9884086.001]
  • [Cites] Biol Psychiatry. 2005 Feb 1;57(3):261-7 [15691527.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Jul;318(1):304-11 [16569753.001]
  • [Cites] Pharmacol Biochem Behav. 2006 Sep;85(1):105-13 [16934319.001]
  • [Cites] Addict Biol. 2008 Jun;13(2):188-95 [18279497.001]
  • [Cites] Addict Behav. 2009 Sep;34(9):782-5 [19464121.001]
  • [Cites] Pharmacol Biochem Behav. 2001 Sep;70(1):123-31 [11566149.001]
  • (PMID = 20363293.001).
  • [ISSN] 1872-7972
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] ENG
  • [Grant] United States / NIDA NIH HHS / DA / P30DA013429; United States / NIDA NIH HHS / DA / P30 DA013429; United States / NIDA NIH HHS / DA / R01 DA17302; United States / NIMH NIH HHS / MH / K01 MH63301; United States / NIDA NIH HHS / DA / R01 DA017302; United States / NIMH NIH HHS / MH / K01 MH063301
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Piperidines; 0 / Psychotropic Drugs; 0 / Pyrazoles; 0 / Receptor, Cannabinoid, CB1; 158681-13-1 / rimonabant; 7J8897W37S / Dronabinol
  • [Other-IDs] NLM/ NIHMS199509; NLM/ PMC3923489
  •  go-up   go-down


86. Gomis M, González LM, Querol F, Gallach JE, Toca-Herrera JL: Effects of electrical stimulation on muscle trophism in patients with hemophilic arthropathy. Arch Phys Med Rehabil; 2009 Nov;90(11):1924-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTERVENTIONS: The hemophilic group followed a surface electrical stimulation program (frequency 45 Hz, impulse 200 micros, 10s on/10s off) over an 8-week period on the biceps brachii of both arms.
  • MAIN OUTCOME MEASURES: The cross-sectional area, maximum voluntary isometric contraction, and EMG activity of the biceps brachii in both arms were determined before and after the 8-week-long task.
  • RESULTS: The results of the hemophilic group showed significant increases in the diameter (15.8%, P<.001), isometric force (4.6%, P<.05), and EMG activity (37.6%, P<.05) of the biceps brachii muscles in both arms.
  • In addition, these results may also be clinically applicable in the rehabilitation of patients who have similar deficiencies in the locomotor system.

  • Genetic Alliance. consumer health - Hemophilic arthropathy.
  • MedlinePlus Health Information. consumer health - Hemophilia.
  • MedlinePlus Health Information. consumer health - Joint Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887218.001).
  • [ISSN] 1532-821X
  • [Journal-full-title] Archives of physical medicine and rehabilitation
  • [ISO-abbreviation] Arch Phys Med Rehabil
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Vianna LC, Oliveira RB, Ramos PS, Ricardo DR, Araújo CG: Effect of muscle mass on muscle mechanoreflex-mediated heart rate increase at the onset of dynamic exercise. Eur J Appl Physiol; 2010 Feb;108(3):429-34
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Fifteen healthy male subjects, 18-30 years old, performed, from the 4th to the 8th second of a 12-s apnea, four different 4-s bouts of passive cycling assigned in a counterbalanced order, each one different from the others by the number of limbs engaged in the movement (i.e., 1 arm, 2 arms, 2 arms + 1 leg and 2 arms + 2 legs), while respiratory movements and limb muscle electromyography were recorded.

  • MedlinePlus Health Information. consumer health - Exercise and Physical Fitness.
  • MedlinePlus Health Information. consumer health - Exercise for Children.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Sci Sports Exerc. 1994 Jun;26(6):709-14 [8052111.001]
  • [Cites] Respir Physiol Neurobiol. 2002 Nov 19;133(3):241-50 [12425971.001]
  • [Cites] Respir Physiol. 1996 Feb;103(2):195-202 [8833551.001]
  • [Cites] Clin Auton Res. 1992 Feb;2(1):35-40 [1638103.001]
  • [Cites] J Physiol. 1973 Dec;235(2):423-36 [4763996.001]
  • [Cites] J Physiol. 1980 Dec;309:45-54 [7252875.001]
  • [Cites] Clin Physiol. 1999 Jul;19(4):294-9 [10451789.001]
  • [Cites] Med Sci Sports Exerc. 1993 Jan;25(1):37-41 [8423755.001]
  • [Cites] Exp Physiol. 2005 Sep;90(5):773-81 [16049058.001]
  • [Cites] J Appl Physiol (1985). 2001 Jan;90(1):308-16 [11133923.001]
  • [Cites] Exp Physiol. 2005 May;90(3):383-91 [15708877.001]
  • [Cites] Clin Auton Res. 2002 Dec;12(6):429-39 [12598947.001]
  • [Cites] J Physiol. 1992 Feb;447:549-62 [1593459.001]
  • [Cites] Exp Physiol. 2004 Nov;89(6):639-46 [15364880.001]
  • [Cites] J Appl Physiol (1985). 1995 Apr;78(4):1273-9 [7615433.001]
  • [Cites] J Physiol. 1996 Jul 15;494 ( Pt 2):601-11 [8842017.001]
  • [Cites] J Physiol. 2005 Sep 1;567(Pt 2):713-21 [15946971.001]
  • [Cites] Acta Physiol (Oxf). 2008 Mar;192(3):351-7 [17973953.001]
  • [Cites] Eur J Appl Physiol. 2006 May;97(2):249-52 [16633826.001]
  • [Cites] Exp Physiol. 2006 Jan;91(1):89-102 [16282366.001]
  • [Cites] Respir Physiol. 1994 Nov-Dec;98(3):251-66 [7899727.001]
  • [Cites] J Appl Physiol (1985). 2005 Nov;99(5):1891-6 [15994238.001]
  • [Cites] Eur J Appl Physiol Occup Physiol. 1985;53(4):359-63 [4039265.001]
  • [Cites] J Appl Physiol (1985). 1989 Nov;67(5):1801-6 [2600014.001]
  • [Cites] J Appl Physiol (1985). 1988 Oct;65(4):1539-47 [3182517.001]
  • [Cites] J Appl Physiol. 1975 Feb;38(2):272-8 [1120751.001]
  • [Cites] J Appl Physiol Respir Environ Exerc Physiol. 1983 Feb;54(2):434-7 [6833040.001]
  • [Cites] Eur J Appl Physiol. 2008 Feb;102(3):283-8 [17929050.001]
  • [Cites] J Pharmacol Exp Ther. 1968 Feb;159(2):298-305 [5638651.001]
  • [Cites] J Physiol. 1999 Oct 15;520 Pt 2:621-8 [10523427.001]
  • [Cites] Eur J Appl Physiol. 2008 Apr;102(6):695-701 [18087683.001]
  • [Cites] J Physiol. 2005 Jun 15;565(Pt 3):1053-60 [15860535.001]
  • [Cites] Exp Physiol. 2006 Jan;91(1):51-8 [16239250.001]
  • (PMID = 19821119.001).
  • [ISSN] 1439-6327
  • [Journal-full-title] European journal of applied physiology
  • [ISO-abbreviation] Eur. J. Appl. Physiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


88. Malyszko J, Zbroch E, Malyszko J, Mysliwiec M, Iaina A: The cardio-renal-anaemia syndrome predicts survival in peritoneally dialyzed patients. Arch Med Sci; 2010 Aug 30;6(4):539-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • INTRODUCTION: Anaemia is one of the arms of the cardio-renal-anaemia syndrome (CRA) in chronic kidney disease (CKD) patients.
  • The severity score = cardiac + renal + anaemia arms score divided by 3 (maximum 4 points).

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 22371797.001).
  • [ISSN] 1896-9151
  • [Journal-full-title] Archives of medical science : AMS
  • [ISO-abbreviation] Arch Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC3284068
  • [Keywords] NOTNLM ; anaemia / chronic heart failure / diabetes / elderly / peritoneal dialysis
  •  go-up   go-down


89. Shimohama T, Ako J, Yamasaki M, Otake H, Tsujino I, Hasegawa T, Nakatani D, Sakurai R, Chang H, Kusano H, Waseda K, Honda Y, Stone GW, Saito S, Fitzgerald PJ, Sudhir K: SPIRIT III JAPAN versus SPIRIT III USA: a comparative intravascular ultrasound analysis of the everolimus-eluting stent. Am J Cardiol; 2010 Jul 1;106(1):13-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The aim of this study was to evaluate the vascular response after everolimus-eluting stent (EES) implantation in the SPIRIT III Japan Registry (JAPAN) compared to EES implantation in the SPIRIT III United States (USA) trial using serial intravascular ultrasound (IVUS) analysis.
  • Late acquired ISA was infrequent in the 2 arms.
  • In conclusion, comparative IVUS analysis between the JAPAN and USA arms showed more optimal stent deployment in the JAPAN arm as evidenced by the lower incidence of postprocedure ISA and larger minimum lumen area after the procedure.
  • [MeSH-major] Coronary Artery Disease / pathology. Coronary Artery Disease / ultrasonography. Drug-Eluting Stents. Randomized Controlled Trials as Topic
  • [MeSH-minor] Aged. Everolimus. Female. Humans. Hyperplasia / ultrasonography. Immunosuppressive Agents / administration & dosage. Japan. Male. Middle Aged. Sirolimus / administration & dosage. Sirolimus / analogs & derivatives. Ultrasonography, Interventional. United States

  • MedlinePlus Health Information. consumer health - Coronary Artery Disease.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. SIROLIMUS .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20609640.001).
  • [ISSN] 1879-1913
  • [Journal-full-title] The American journal of cardiology
  • [ISO-abbreviation] Am. J. Cardiol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; 9HW64Q8G6G / Everolimus; W36ZG6FT64 / Sirolimus
  •  go-up   go-down


90. Cohen MH, Justice R, Pazdur R: Approval summary: pemetrexed in the initial treatment of advanced/metastatic non-small cell lung cancer. Oncologist; 2009 Sep;14(9):930-5
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The median progression-free survival times were 4.8 and 5.1 months for the AC and GC arms, respectively (adjusted HR, 1.04; 95% CI, 0.94-1.15).
  • The overall response rates were 27.1% and 24.7% for the AC and GC arms, respectively.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Cisplatin / administration & dosage. Cisplatin / therapeutic use. Clinical Trials, Phase III as Topic. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Disease-Free Survival. Female. Humans. Male. Middle Aged. Pemetrexed. Survival Analysis. Time Factors. United States. United States Food and Drug Administration


91. Stinco G, Piccirillo F, Valent F: A randomized double-blind study to investigate the clinical efficacy of adding a non-migrating antimicrobial to a special silk fabric in the treatment of atopic dermatitis. Dermatology; 2008;217(3):191-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The inclusion criterion was that the patients presented with active AD with eczematous lesions located on the arms without any sign of infection.
  • RESULTS: The mean local SCORAD index of both the DermaSilk- and the unmodified-silk-covered arms decreased significantly between baseline (T0) and the end of study (T28).


92. De D, Dogra S, Saikia UN, Kanwar AJ: An unusual presentation of mucous membrane pemphigoid. Skinmed; 2008 Jan-Feb;7(1):45-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual presentation of mucous membrane pemphigoid.
  • The disease had started as tense blisters associated with a burning sensation over the lower part of her back, gradually followed by involvement of her chest, upper part of her back, and arms.
  • Cutaneous examination revealed a few tense bullae on normal-looking skin over her abdomen (Figure 2 inset) and arms and areas of scarring at the site of healed lesions on her back.
  • Examination of the other mucosae did not reveal any abnormality.
  • Direct immunofluorescence of a biopsy specimen from perilesional skin revealed linear deposits of immunoglobulins M and G and of C3 at the dermoepidermal junction which was consistent with mucous membrane pemphigoid.
  • [MeSH-major] Pemphigoid, Benign Mucous Membrane / pathology

  • MedlinePlus Health Information. consumer health - Pemphigus.
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. DAPSONE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18174805.001).
  • [ISSN] 1540-9740
  • [Journal-full-title] Skinmed
  • [ISO-abbreviation] Skinmed
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Inflammatory Agents; 0 / Dermatologic Agents; 8W5C518302 / Dapsone; 9PHQ9Y1OLM / Prednisolone
  •  go-up   go-down


93. Llombart-Cussac A, Martin M, Harbeck N, Anghel RM, Eniu AE, Verrill MW, Neven P, De Grève J, Melemed AS, Clark R, Simms L, Kaiser CJ, Ma D: A randomized, double-blind, phase II study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer. Clin Cancer Res; 2007 Jun 15;13(12):3652-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The P600 (47 patients) and P900 (45 patients) arms had response rates of 17.0% (95% confidence interval, 7.7-30.8%) and 15.6% (95% confidence interval, 6.5-29.5%) with approximately 50% stable disease per arm, median progression-free survival of 4.2 and 4.1 months, and median times to tumor progression of 4.2 and 4.6 months, respectively.
  • Both arms exhibited minimal toxicity (grade 3/4 neutropenia <20%, leukopenia <9%, and other toxicities <5%).

  • Genetic Alliance. consumer health - Breast Cancer.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. PEMETREXED .
  • Hazardous Substances Data Bank. FOLIC ACID .
  • Hazardous Substances Data Bank. CYANOCOBALAMIN .
  • Hazardous Substances Data Bank. GUANINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17575230.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Biomarkers, Tumor; 0 / Glutamates; 0 / RNA, Messenger; 04Q9AIZ7NO / Pemetrexed; 5Z93L87A1R / Guanine; 935E97BOY8 / Folic Acid; P6YC3EG204 / Vitamin B 12
  •  go-up   go-down


94. Lawton CA, DeSilvio M, Roach M 3rd, Uhl V, Kirsch R, Seider M, Rotman M, Jones C, Asbell S, Valicenti R, Hahn S, Thomas CR Jr: An update of the phase III trial comparing whole pelvic to prostate only radiotherapy and neoadjuvant to adjuvant total androgen suppression: updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys; 2007 Nov 1;69(3):646-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: This trial was designed to test the hypothesis that total androgen suppression and whole pelvic radiotherapy (WPRT) followed by a prostate boost improves progression-free survival (PFS) by > or =10% compared with total androgen suppression and prostate only RT (PORT).
  • This trial was also designed to test the hypothesis that neoadjuvant hormonal therapy (NHT) followed by concurrent total androgen suppression and RT improves PFS compared with RT followed by adjuvant hormonal therapy (AHT) by > or =10%.
  • Patients were stratified by T stage, prostate-specific antigen level, and Gleason score and were required to have an estimated risk of lymph node involvement of >15%.
  • RESULTS: The difference in overall survival for the four arms was statistically significant (p = 0.027).
  • A trend towards a difference was found in PFS (p = 0.065) in favor of the WPRT + NHT arm compared with the PORT + NHT and WPRT + AHT arms.
  • Four Phase III trials have demonstrated better outcomes when NHT was combined with RT compared with RT alone.
  • The Radiation Therapy Oncology Group 9413 trial results have demonstrated that when NHT is used in conjunction with RT, WPRT yields a better PFS than does PORT.

  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Control Clin Trials. 1984 Mar;5(1):55-66 [6713908.001]
  • [Cites] J Clin Oncol. 2003 Nov 1;21(21):3972-8 [14581419.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1993 Jan 15;25(2):299-307 [8420878.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jan 1;28(1):33-7 [7505775.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Mar 15;37(5):1035-41 [9169810.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1285-90 [15817329.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Nov 1;66(3):647-53 [17011443.001]
  • [Cites] J Urol. 1993 Dec;150(6):1923-4 [7693984.001]
  • [Cites] Control Clin Trials. 1984 Dec;5(4):348-61 [6518769.001]
  • [Cites] N Engl J Med. 2003 Jan 16;348(3):203-13 [12529460.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1243-52 [11483335.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jun 1;47(3):617-27 [10837944.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14565-70 [11734652.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jun 1;53(2):304-15 [12023134.001]
  • [Cites] Lancet. 2002 Jul 13;360(9327):103-6 [12126818.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):316; author reply 316 [18406900.001]
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2008 May 1;71(1):315; author reply 315-6 [18406897.001]
  • (PMID = 17531401.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA096216-05S3; United States / NCI NIH HHS / CA / U56 CA096216; United States / NCI NIH HHS / CA / U56 CA096216-05S3
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Androgen Antagonists; EC 3.4.21.77 / Prostate-Specific Antigen
  • [Other-IDs] NLM/ NIHMS31871; NLM/ PMC2917177
  •  go-up   go-down


95. Harris RZ, Salfi M, Sullivan JT, Padhi D: Pharmacokinetics of cinacalcet hydrochloride when administered with ketoconazole. Clin Pharmacokinet; 2007;46(6):495-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND OBJECTIVE: The calcimimetic cinacalcet hydrochloride (cinacalcet) is used for treatment of patients with chronic kidney disease with secondary hyperparathyroidism, a population that commonly receives multiple concurrent medications.
  • Pharmacokinetic parameters were analysed using a crossover ANOVA model that included subjects who completed both treatment arms.
  • RESULTS: Twenty subjects completed both treatment arms.
  • [MeSH-major] Antifungal Agents / pharmacology. Cytochrome P-450 Enzyme System / metabolism. Ketoconazole / pharmacology. Naphthalenes / pharmacokinetics

  • Hazardous Substances Data Bank. KETOCONAZOLE .
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pharmacol. 1998 Oct 9;358(3):289-94 [9822896.001]
  • [Cites] Mol Pharmacol. 1989 Jul;36(1):89-96 [2787473.001]
  • [Cites] Kidney Int. 2005 Feb;67(2):760-71 [15673327.001]
  • [Cites] Antimicrob Agents Chemother. 1984 Jan;25(1):1-3 [6322675.001]
  • [Cites] Drug Metab Dispos. 2004 Dec;32(12):1491-500 [15328250.001]
  • [Cites] Am J Kidney Dis. 2005 Jul;46(1):58-67 [15983958.001]
  • [Cites] Clin Pharmacol Ther. 1994 May;55(5):481-5 [8181191.001]
  • [Cites] Am J Kidney Dis. 2003 Oct;42(4 Suppl 3):S1-201 [14520607.001]
  • [Cites] Clin Pharmacol Ther. 1996 Mar;59(3):297-303 [8653992.001]
  • [Cites] Clin Pharmacol Ther. 1999 Nov;66(5):461-71 [10579473.001]
  • [Cites] J Am Soc Nephrol. 2005 Mar;16(3):800-7 [15689407.001]
  • [Cites] Am J Kidney Dis. 2004 Dec;44(6):1070-6 [15558528.001]
  • [Cites] Curr Drug Metab. 2004 Oct;5(5):415-42 [15544435.001]
  • [Cites] Clin Pharmacol Ther. 1994 Dec;56(6 Pt 1):601-7 [7995001.001]
  • [Cites] N Engl J Med. 2004 Apr 8;350(15):1516-25 [15071126.001]
  • [Cites] J Clin Pharmacol. 2003 May;43(5):443-69 [12751267.001]
  • [Cites] Clin Pharmacokinet. 2000 Jan;38(1):41-57 [10668858.001]
  • [Cites] Drug Metab Dispos. 1993 May-Jun;21(3):403-9 [8100494.001]
  • [Cites] J Am Soc Nephrol. 2004 Aug;15(8):2208-18 [15284307.001]
  • [Cites] Clin Pharmacokinet. 2000 Feb;38(2):111-80 [10709776.001]
  • [Cites] J Pharm Pharm Sci. 1999 May-Aug;2(2):47-52 [10952769.001]
  • (PMID = 17518508.001).
  • [ISSN] 0312-5963
  • [Journal-full-title] Clinical pharmacokinetics
  • [ISO-abbreviation] Clin Pharmacokinet
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase I; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Naphthalenes; 1K860WSG25 / Cinacalcet Hydrochloride; 9035-51-2 / Cytochrome P-450 Enzyme System; EC 1.14.13.67 / CYP3A4 protein, human; EC 1.14.14.1 / Cytochrome P-450 CYP3A; R9400W927I / Ketoconazole; SY7Q814VUP / Calcium
  •  go-up   go-down


96. Southwest Oncology Group, Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED: Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone. J Clin Oncol; 2006 Jun 20;24(18):2828-35
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • While Southwest Oncology Group trial 99-16 demonstrated a survival improvement of DE over MP, the study also was designed to compare the palliation of disease-related symptoms.
  • There were no statistically significant differences in pain palliation between the treatment arms.
  • The sensitivity analyses showed a consistent lack of statistically significant global QOL differences for the two arms.


97. Valmaggia LR, Freeman D, Green C, Garety P, Swapp D, Antley A, Prescott C, Fowler D, Kuipers E, Bebbington P, Slater M, Broome M, McGuire PK: Virtual reality and paranoid ideations in people with an 'at-risk mental state' for psychosis. Br J Psychiatry Suppl; 2007 Dec;51:s63-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Virtual reality and paranoid ideations in people with an 'at-risk mental state' for psychosis.
  • AIMS: To establish the feasibility and safety of using virtual reality methodology in people with an at-risk mental state and to investigate the applicability of a cognitive model of paranoia to this group.
  • METHOD: Twenty-one participants with an at-risk mental state were assessed before and after entering a virtual reality environment depicting the inside of an underground train.
  • Individuals attributed mental states to virtual reality characters including hostile intent.
  • CONCLUSIONS: Virtual reality is an acceptable experimental technique for use with individuals with at-risk mental states.

  • MedlinePlus Health Information. consumer health - Psychotic Disorders.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18055940.001).
  • [ISSN] 0960-5371
  • [Journal-full-title] The British journal of psychiatry. Supplement
  • [ISO-abbreviation] Br J Psychiatry Suppl
  • [Language] eng
  • [Grant] United Kingdom / Wellcome Trust / / 062452
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


98. Duerkop BA, Vaishnava S, Hooper LV: Immune responses to the microbiota at the intestinal mucosal surface. Immunity; 2009 Sep 18;31(3):368-76
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Here we discuss recent insights into how the innate and adaptive arms of the immune system collaborate to maintain homeostasis at the luminal surface of the intestinal host-microbial interface.
  • These findings are also yielding a better understanding of how symbiotic host-microbial relationships can break down in inflammatory bowel disease.

  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19766080.001).
  • [ISSN] 1097-4180
  • [Journal-full-title] Immunity
  • [ISO-abbreviation] Immunity
  • [Language] eng
  • [Grant] United States / Howard Hughes Medical Institute / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Number-of-references] 84
  •  go-up   go-down


99. Vaishnavi S, Gadde K, Alamy S, Zhang W, Connor K, Davidson JR: Modafinil for atypical depression: effects of open-label and double-blind discontinuation treatment. J Clin Psychopharmacol; 2006 Aug;26(4):373-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Atypical depression, with features of hypersomnia, hyperphagia, anergia, and rejection sensitivity, is a common presentation of major depressive disorder.
  • There are few available effective therapies for this disorder.
  • We found that modafinil significantly improved atypical depression symptoms during 12 weeks of open-label treatment (mean +/- SD Hamilton Depression Scale (29-item version) score changed from 34 +/- 8.2 at baseline to 9.7 +/- 9.3, P < 0.0001), and that benefits were maintained alike in both the continuation and placebo arms during the double-blind treatment phase (P = 0.92).
  • [MeSH-major] Benzhydryl Compounds / therapeutic use. Depressive Disorder / drug therapy
  • [MeSH-minor] Adult. Aged. Central Nervous System Stimulants / administration & dosage. Central Nervous System Stimulants / adverse effects. Central Nervous System Stimulants / therapeutic use. Disorders of Excessive Somnolence / drug therapy. Double-Blind Method. Female. Headache / chemically induced. Humans. Hyperphagia / drug therapy. Male. Middle Aged. Nausea / chemically induced. Patient Dropouts. Patient Selection. Thirst / drug effects. Time Factors. Treatment Outcome. Weight Loss / drug effects. Withholding Treatment

  • Genetic Alliance. consumer health - Depression.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. MODAFINIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] J Clin Psychopharmacol. 2006 Oct;26(5):523
  • (PMID = 16855454.001).
  • [ISSN] 0271-0749
  • [Journal-full-title] Journal of clinical psychopharmacology
  • [ISO-abbreviation] J Clin Psychopharmacol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzhydryl Compounds; 0 / Central Nervous System Stimulants; R3UK8X3U3D / modafinil
  •  go-up   go-down


100. Lalonde R, Kim HD, Maxwell JA, Fukuchi K: Exploratory activity and spatial learning in 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice with amyloid plaques. Neurosci Lett; 2005 Dec 23;390(2):87-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • On the initial testing day, 12-month-old APP(695)SWE/co+PS1/DeltaE9 mice spent more time than non-transgenic controls in the open arms of the elevated plus-maze.

  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16169151.001).
  • [ISSN] 0304-3940
  • [Journal-full-title] Neuroscience letters
  • [ISO-abbreviation] Neurosci. Lett.
  • [Language] eng
  • [Grant] United States / NINDS NIH HHS / NS / NS43947
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Amyloid beta-Protein Precursor
  •  go-up   go-down






Advertisement